A Brain-Derived Neurotrophic Factor-Based p75\textsuperscript{NTR} Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination

David G. Gonsalvez,1 Giang Tran,3 @Jessica L. Fletcher,1 Richard A. Hughes,2 Suzanne Hodgkinson,3 Rhiannon J. Wood,1 Sang Won Yoo,1 Mithraka De Silva,1 Wong W. Agnes,1 Catriona McLean,4 Paul Kennedy,4 @Trevor J. Kilpatrick,1 @Simon S. Murray,1 and Junhua Xiao1

DOI: http://dx.doi.org/10.1523/ENEURO.0142-17.2017

1Department of Anatomy and Neuroscience, The University of Melbourne, VIC 3010, Australia, 2Department of Pharmacology and Therapeutics, The University of Melbourne, VIC 3010, Australia, 3Liverpool Hospital, The University of New South Wales, NSW 2170, Australia, and 4Victorian Neuromuscular Laboratory Services, Alfred Health, VIC 3004, Australia

Abstract

Axonal damage and demyelination are major determinants of disability in patients with peripheral demyelinating neuropathies. The neurotrophin family of growth factors are essential for the normal development and myelination of the peripheral nervous system (PNS), and as such are potential therapeutic candidates for ameliorating axonal and myelin damage. In particular, BDNF promotes peripheral nerve myelination via p75 neurotrophin receptor (p75\textsuperscript{NTR}) receptors. Here, we investigated the therapeutic efficacy of a small structural mimetic of the region of BDNF that binds to p75\textsuperscript{NTR} (cyclo-\textalpha-PAKKR) in experimental autoimmune neuritis (EAN), an established animal model of peripheral demyelinating neuropathy. Examination of rodents induced with EAN revealed that p75\textsuperscript{NTR} is abundantly expressed in affected peripheral nerves. We found that systemic administration of cyclo-\textalpha-PAKKR ameliorates EAN disease severity and accelerates recovery. Animals treated with cyclo-\textalpha-PAKKR displayed significantly better motor performance compared to control animals. Histological assessment revealed that cyclo-\textalpha-PAKKR administration limits the extent of inflammatory demyelination and axonal damage, and protects against the disruption of nodal architecture in affected peripheral nerves. In contrast, a structural control peptide of cyclo-\textalpha-PAKKR exerted no influence. Moreover, all the beneficial effects of cyclo-\textalpha-PAKKR in EAN are abrogated in p75\textsuperscript{NTR} heterozygous mice, strongly suggesting a p75\textsuperscript{NTR}-dependent effect. Taken together, our data demonstrate that cyclo-\textalpha-PAKKR ameliorates functional and pathological defects of EAN in a p75\textsuperscript{NTR}-dependant manner.

Significance Statement

This study demonstrates that a BDNF-based peptide mimetic ameliorates the clinical and functional deficits in experimental autoimmune neuritis (EAN), an animal model of peripheral demyelinating neuropathy. Concordant with these findings, treatment significantly reduced immune cell infiltration, the extent of peripheral demyelination and axonal pathology. Genetic analyses identified these effects were mediated through p75 neurotrophin receptor (p75\textsuperscript{NTR}). This study identifies a novel avenue for myelin and axonal protection in peripheral demyelinating neuropathy through targeting p75\textsuperscript{NTR}, however, additional studies are required to identify the precise cellular mechanism underlying these effects. The strong protective effect that the mimetic exerts on axonal damage paves the way for studying its application in other peripheral neuropathies in the future.
suggesting that p75NTR is a therapeutic target to consider for future treatment of peripheral demyelinating diseases and targeting of p75NTR is a strategy worthy of further investigation.

**Key words:** axonal damage; BDNF; demyelination; experimental autoimmune neuritis; p75NTR

**Introduction**

Demyelination and axonal degeneration are pathologic hallmarks of injured peripheral nerve in acquired demyelinating peripheral neuropathies (Hughes et al., 2007). However, current therapies for these diseases are anti-inflammatory and do not prevent neurologic symptoms underpinned by persistent demyelination and secondary axonal degeneration (Hughes et al., 2007), demonstrating a need for novel neuroprotective therapies that can be administered as adjuncts to existing immunomodulatory therapies for the treatment of these diseases.

The neurotrophins are a family of soluble growth factors essential for peripheral nervous system (PNS) development and myelination (Chan et al., 2001; Cosgaya et al., 2002; Xiao et al., 2009a). They comprise nerve growth factor (NGF), BDNF, neurotrophin (NT)-3, and NT-4/5. Their biological effects are mediated via two distinct classes of receptors: the tropomyosin-related kinase (Trk) receptors and the p75 neurotrophin receptor (p75NTR; Kaplan and Miller, 2000). Different neurotrophins exert distinct influences on peripheral myelination depending on the cognate receptor expressed by peripheral neurons (Xiao et al., 2009a). We and others have demonstrated that BDNF promotes myelination via acting on p75NTR (Cosgaya et al., 2002; Xiao et al., 2009b), whereas it inhibits myelination via activating TrkB (Xiao et al., 2009b). Moreover, analyses of mutant mice indicate that p75NTR is required for the survival of a subset of peripheral neurons (Lee et al., 1992). In this context, selective targeting of p75NTR could be an approach that, in principle, exerts a beneficial effect on myelin repair and protection against axonal damage after peripheral nerve injury.

This has led us to develop the cyclic pentapeptide cyclo-[Pro-Ala-Lys-Arg] (cyclo-dPAKKR), a structural mimic of BDNF (Fletcher et al., 2008). Cyclo-dPAKKR is presented in a highly conformationally constrained cyclic template that contains the positively charged ‘Lys-Lys-Arg’ tri-peptide motif required for BDNF to bind to p75NTR (Rydén et al., 1995). Importantly, cyclo-dPAKKR contains no sequence similarity to the loop 2 region of BDNF that binds TrkB and does not cause TrkB autophosphorylation (Fletcher et al., 2008). Equally, it contains no sequence similarity to the N-terminal portion of pro-BDNF that binds the sortilin-p75NTR receptor complex and does not induce the death of sensory neurons or Schwann cells in culture (Fletcher et al., 2008). Cyclo-dPAKKR displays drug-like properties, in that it is of low molecular weight (relative molecular mass of 580), metabolically stable in rodent plasma in vitro and readily crosses cell membranes (Fletcher et al., 2008; Fletcher and Hughes, 2009). Collectively, these properties of cyclo-dPAKKR render it a unique pharmacological tool to investigate the selective influence of BDNF on p75NTR, without the concomitant activation of TrkB or the sortilin-p75NTR proneurotrophin receptor complex. Indeed, we have previously shown that cyclo-dPAKKR promotes the survival of peripheral neurons in vitro (Fletcher et al., 2008) and peripheral nerve myelination in vitro and in vivo, an effect dependent on the expression of p75NTR (Xiao et al., 2013).

In this study, we investigated the therapeutic potential of cyclo-dPAKKR in experimental autoimmune neuritis (EAN), a well-established model of demyelinating peripheral neuropathy. The disease course mirrors many of the morphologic and electrophysiological aspects of acute and chronic demyelinating peripheral neuropathy, given that on the one hand there is acute remission but that on the other hand there is incomplete recovery (Mäurer and Gold, 2002; Hughes and Comblath, 2005; Yuki and Hartung, 2012). We found that p75NTR is abundantly expressed in affected peripheral nerves in rodent EAN. Systemic administration of cyclo-dPAKKR ameliorates EAN disease course and motor deficits, and reduces the extent of demyelination and axonal damage, in a p75NTR-dependent manner. In contrast, a structural control peptide of cyclo-dPAKKR exerted no influence. Our data demonstrate that cyclo-dPAKKR exerts p75NTR-dependent neuroprotective effects in EAN, suggesting that targeting of p75NTR is a strategy worthy of further investigation for the treatment of peripheral demyelinating diseases.

**Materials and Methods**

**Animals**

EAN disease was induced in Lewis rats (10–12 weeks old, female) bred and maintained at the Liverpool Hospital Animal Facility, New South Wales, and in C57B6 wild-type (WT, +/+ ) and NGFR/C57B6 (p75NTR heterozygous, HET, +/− ) mice housed at the Animal Facility of Florey Institute of Neuroscience and Mental Health Research, the University of Melbourne. The p75NTR HET mice were obtained from a colony previously shown to be 95% congenic to...
the inbred C57B6 strain (Syroid et al., 2000), and subsequently back-crossed a further 12 generations. All animal procedures were approved by Animal Experimentation Ethics Committees at the University of New South Wales and University of Melbourne.

Peptide syntheses and reagents
The conformationally-constrained cyclised active peptide cyclo-dPAKKR (dPro-Ala-Lys-Lys-Arg) and control peptide (Ala-dPro-Lys-Lys-Arg, cyclo-ADPKKR) were synthesised, purified and characterised as previously described (Fletcher et al., 2008; Xiao et al., 2013). All chemicals were obtained from Sigma-Aldrich unless otherwise indicated.

EAN induction in rats
Adult Lewis rats were induced with EAN disease by inoculation with a peripheral myelin antigen using published methods (Hodgkinson et al., 1994; Tran et al., 2010, 2012). Briefly, 10- to 12-week-old female rats were immunized in the footpad with 200 μl of emulsion containing 4mg bovine peripheral nerve myelin and 1.5 mg of complete Freund’s adjuvant prepared by emulsifying heat killed Mycobacterium tuberculosis (strain H37RA; Difco) in 100 μl saline and 100 μl incomplete Freund’s adjuvant (Difco). Animals develop a severe disease initially consisting of paraplegia and eventually quadriplegia. Animals were monitored daily for weight loss, and clinical disease was scored as 0 for normal, 1 for limp tail, 2 for hind leg weakness, 3 for paraplegia, and 4 for quadriplegia.

EAN induction in mice
Adult C57/B6 mice were induced with EAN disease as previously described (Gonsalvez et al., 2017). Briefly, six- to eight-week-old male mice (WT and p75 HET) were immunized twice (day 0 and day 8 after induction) by subcutaneous injection of myelin basic protein zero (P0) peptide 180–199 (P0180–199, sequence S-S-K-R-G-R-Q-T-P-V-L-Y-A-M-L-D-H-S-R-S), and 0.5 mg Mycobacterium tuberculosis (strain H 37 Ra; Difco) in 25 μl of paraffin oil and 12.5 μl of incomplete Freund’s adjuvant (Difco). Animals were killed desiccated killed and dried Myobacterium butyrcum). Mice received pertussis toxin (Ptx, Sigma) on day 1, days 3 (150 ng/mouse), and days 1 and 3 (300 ng/mouse) by intraperitoneal injection. All Ptx and inoculation injections were conducted on mice anesthetized by aerosol isoflurane 2% in normal air. Animals were monitored daily for weight loss, and clinical disease was scored as: 0 for normal, 1 for less lively, 2 for mild tail and hindlimb paresis, 3 for mild ataxia and limb paresis, 4 for severe ataxia and limb paresis and 5 for limb paralysis.

Cyclo-dPAKKR treatment
EAN animals were intraperitoneally administered with cyclo-dPAKKR (0.1–10 mg/kg/d) or vehicle control (PBS) daily after the day of disease induction (day 0). The doses of cyclo-dPAKKR were chosen based on its potency in promoting peripheral nerve myelination in vivo (Xiao et al., 2013). Rats were killed at day 17, the peak of clinical disease and when demyelination is maximal, or at day 24 when animals exhibit partial recovery (Tran et al., 2010, 2012). Cauda equina and sciatic nerves were dissected and prepared for Western blot, immunohistochemical, histologic, or electron microscopy (EM) analyses as described previously (Tran et al., 2002; Xiao et al., 2013). Six to seven rats per treatment group per time point were assessed. In some experiments, cyclo-dPAKKR (10 mg/kg/d), the control peptide (cyclo-AdPKKR, 10 mg/kg/d) or a vehicle (PBS) control was intraperitoneally administered to mice (p75NTR HET and WT littermate controls) via mini osmotic pump (ALZET, CA: pump#: 2006). Mice sciatic nerves were collected at day 23 (disease peak in murine EAN) and six mice per genotype per treatment group were assessed.

Quantitative PCR (qPCR)
Total RNA was extracted from cauda equina and sciatic nerves of healthy control rats and rats subjected to EAN at day 17 using the QiAGEN RNEasy kit. Extracted RNA was reverse transcribed into cDNA, using Taqman Reverse Transcription reagents (Applied Biosystems). qPCRs were performed on an Applied Biosystem ABI7700 sequence detection system and analyzed using the comparative Ct method. Sequences of primers used were as follows: rat 18S, forward 5’-GCTGGAATTACCGCGGCT-3’, reverse 5’-CGGTGACCATCAAGAAA-3’; p75NTR, forward 5’-AAAGGCAGGCGGATTGTGTA-3’, reverse 5’-GTGCGGTAGGGCTCAAGTGT-3’. Data are relative to 18S then normalized against the healthy control.

Western blot analysis
To assess myelin protein expression, total protein lysates were prepared from cauda equina and sciatic nerves from EAN rats, separated by SDS-PAGE and transferred to PVDF membrane. Membranes were probed with an antibody against myelin basic protein (MBP; AB980, Millipore Bioscience Research Reagents), a myelin marker, and actin as a loading control. Each blot shown in the figure is a representative of at least three independent experiments. Quantification of the Western blot bands was achieved by scanning the blots using a FujiFilm LAS-3000 (FujiFilm). The optical density value for each band was determined using NIH ImageJ, corrected to a loading control, and then normalized against the vehicle control conditions.

Animal immunohistochemistry
EAN animals (rats and mice) were perfused transcardially with 4% PFA, cauda equina and/or sciatic nerves isolated, frozen, and 10 μm cryosections separated by at least 80 μm collected. The cauda equina or sciatic nerve sections were immunostained with the myelin marker MBP (AB980, Millipore Bioscience Research Reagents), amyloid precursor protein (APP; S12700, Invitrogen), pan voltage-gated Sodium channel (pan-Nav, S8809, Sigma), contactin-associated protein 1 (Caspr, a generous gift from Professor Elior Peles, Weizmann Institute of Science, Israel; Gordon et al., 2014), βIII-tubulin (G7121, Promega), IBA1 (WAKO, 019-19741), or p75NTR (G323A, Promega), followed by the appropriate fluorophore-conjugated sec-
ondary antibodies (Invitrogen). The sections were then washed in PBS, and mounted in DAKO mounting medium with DAPI. Six sections per animal from a minimum of three animals per group were analyzed, and images captured by confocal microscopy. The proportion of labeled cells per section was calculated for each animal, and averaged across groups.

**Transmission EM**

Rats were perfused with 4% PFA, cauda equina dissected, postfixed overnight at 4°C in Karnovsky’s fixative, and subsequently processed for resin embedding, as previously described (Xiao et al., 2011, 2013). Semi-thin sections (0.5 μm) were cut and stained with toluidine blue and bright field image taken at 100× magnification. Representative samples were then chosen, and ultrathin sections (90 nm) were cut. EM images were captured using a Siemens Stereoskop Transmission Electron Microscope (Siemens) at 3000× magnification. For quantification, three to four animals per treatment group were used, and minimum six images per animal were taken randomly and analyzed covering the majority of the nerve sections.

**Spectral reflectance confocal microscopy imaging**

Spectral reflectance confocal microscopy (SCoRe) imaging was performed on sciatic nerve sections to assess the extent of myelin damage in EAN mice using published methods (Schain et al., 2014). Briefly, mice were perfused with 4% PFA, sciatic nerves dissected (2 mm proximal to the bifurcation of the common peroneal and tibial division), frozen and cryosectioned at 12 μm. Longitudinal sections of sciatic nerves were imaged via a Zeiss 780 Meta confocal microscope with a water immersion objective (Zeiss W Plan-Apochromat 20×/1.0 NA DIC M27 70mm) using 458, 561, and 633-nm laser wavelength through the Tunable Lazer In Tune 488–640 filter/splitter wheel and a 20/80 partially reflective mirror. The reflected light was collected using three photodetectors set to collect light through narrow bands defined by prism and mirror sliders, centered around the laser wavelengths 488, 561, and 633 nm. The channels from each photodetector were then additively combined as a one color composite. All images were acquired using the same settings, analyzed by an operator blinded to conditions using NIH Fiji (ImageJ) software with the threshold function and a minimum cutoff for positive pixels set at 50. The percentage area of positive signal was computed for each image. For quantification, a minimum three tile scans (three images per tile, using a 20×/1.0NA objective at a z-depth 4 μm from the tissue surface) per treatment group were used and statistically analyzed.

**Functional running task assessment**

To assess functional outcomes following cyclo-DPAKKR treatment in EAN, animals were videored on a transparent treadmill using the DigiGait 8 program system (eMouse Specifics) as previously described (Gonsalvez et al., 2017). A simple running task was designed, in which mice were set to complete a 36-s run at a treadmill speed of 15 cm/s. Mice that could not maintain running for the 36-s interval were deemed to fail, as described previously (Gonsalvez et al., 2017). During the running task, video was captured and the running time before failure was analyzed using the DigiGait 8 program. Mice were tested with the running task every 3 d. It typically took 15- to 20-s running time for mice to successfully complete 10 continuous uninterrupted steps as previously described (Gonsalvez et al., 2017).

**Statistical analysis**

All data are presented as mean ± SEM, or mean ± 95% confidence interval. Differences between pairs of groups for clinical scores were tested by Mann–Whitney U test. Repeated measures two-way ANOVA testing was used to determine the interaction between groups and time, and genotypes, in all cases significance was set at p < 0.05. All statistical testing was performed using GraphPad Prism 6 software.

**Results**

**Expression of p75NTR is increased in EAN nerves**

to investigate whether targeting p75NTR is a potential therapeutic strategy for treating peripheral demyelinating diseases, we sought to first determine the level of p75NTR expression in injured peripheral nerves of rats subjected to EAN at disease peak (day 17) and age-matched health control (non EAN) rats (Fig. 1). We found a low level of p75NTR expression detected in the cauda equina of healthy adult rats (Fig. 1A), whereas abundant p75NTR expression was observed in the cauda equina of rats subjected to EAN (Fig. 1B). Further, qPCR analysis revealed a significant increase in p75NTR mRNA expression in the cauda equina and sciatic nerves of rats subjected to EAN compared with age-matched healthy control rats (Fig. 1C, n = 3–4/group, *p < 0.05). Thus, our results demonstrate that p75NTR expression (both mRNA and protein) is increased in the effected peripheral nerves of rats subjected to EAN.

**Cyclo-DPAKKR ameliorates EAN disease severity in a dose-dependent manner**

To investigate whether targeting p75NTR via cyclo-DPAKKR exerts any beneficial influence on EAN, rats received daily intraperitoneal administration of cyclo-DPAKKR over four orders of magnitude (0.1, 1, 3, and 10 mg/kg) or vehicle control (saline) from day 1 (1 day after disease induction) for 17 d. Our data show that cyclo-DPAKKR administration significantly ameliorated EAN disease severity at the two higher doses (3 mg/kg: *p < 0.01 and 10 mg/kg: *p < 0.001), but not the two lower doses (0.1 mg/kg: p = 0.78 and 1 mg/kg: p = 0.15), compared with the vehicle control (Fig. 2A). In addition, animals treated with cyclo-DPAKKR at 10 mg/kg, but not 3 mg/kg, displayed a significant delay (~3 d) in the onset of EAN disease compared with the vehicle control group (Fig. 2A, *p < 0.05).

EAN disease in rats is a monophasic disease that exhibits a stereotypical progression. Following the disease peak at approximately day 17, animals usually undergo a limited degree of spontaneous recovery with a reduction
in disease severity (Tran et al., 2010). We next sought to determine if the administration of cyclo-DPAKKR beyond the peak of disease (day 17) ameliorates disease progression and promotes recovery. To do this, EAN was induced in a separate cohort of rats that received daily intraperitoneal administration of cyclo-DPAKKR (10 mg/kg) or vehicle from day 1 for 24 d (Fig. 2B). Concordant with the data above (Fig. 2A), cyclo-DPAKKR administration significantly delayed the disease onset (–3 d) compared with vehicle-treated control rats (Fig. 2B, *p < 0.05). Delivery of cyclo-DPAKKR beyond the peak of disease continued to ameliorate EAN disease severity compared with the vehicle-treated control group, with animals treated with cyclo-DPAKKR displaying a more rapid reduction in disease scores during the recovery phase compared with vehicle-treated control animals (Fig. 2B, n = 6–7 mice/group, *p < 0.01), suggesting that treatment with cyclo-DPAKKR beyond disease peak accelerates recovery in EAN.

**Cyclo-DPAKKR abrogates myelin damage in EAN**

Demyelination and axonal degeneration are key pathologic features of rodents with EAN and patients with demyelinating peripheral neuropathy, and ultimately influences disease prognosis (Nagappan and Lu, 2005). Having shown that cyclo-DPAKKR ameliorates the clinical deficits in rat EAN (Fig. 2), we next sought to determine the neuropathological basis for its beneficial effects. We first measured expression of the integral myelin protein MBP in injured peripheral nerves via Western blot and immunohistochemical analyses (Fig. 3A–D). Both sciatic nerves and cauda equina were dissected at days 17 and 24, followed by total protein extraction and probing with an antibody directed against MBP. We found significantly more MBP expression in both peripheral nerves of EAN rats treated with cyclo-DPAKKR at both time points compared with vehicle-treated controls (Fig. 3A,B, *p < 0.05). This result was confirmed by assessing MBP protein expression on cauda equina sections using immunohistochemistry (Fig. 3C,D, *p < 0.05). Collectively, these data suggest that cyclo-DPAKKR administration protects against the loss of myelin protein expression in injured peripheral nerves of EAN animals in vivo.

To further determine the extent of myelin pathology in these animals, we undertook an ultrastructural analysis of myelinated axons via histology and EM (Fig. 3E–H). We first assessed the percentage of myelinated axons at two time points (days 17 and 24). Our data revealed significantly more myelinated axons in the cauda equina of rats subjected to EAN and treated with cyclo-DPAKKR compared with vehicle-treated controls at both time points (Fig. 3E, quantitated in F, *p < 0.05). We also examined the density of axons, calculating the data as a percentage relative to healthy control (no EAN) rats (Fig. 3E, quantitated in G). We also quantitated axonal numbers and found that the number of axons in vehicle-treated animals was significantly reduced to 30–40% of the healthy control, whereas cyclo-DPAKKR administration protected against axonal loss at disease peak and during recovery (~60% of healthy control; Fig. 3G, n = 3–4/group/time point, *p < 0.05), supporting out prior finding that cyclo-DPAKKR treatment reduces the extent of demyelination at the peak of disease and during the recovery phase in EAN (Fig. 3F).

To further determine if cyclo-DPAKKR exerts a protective influence on myelin integrity in EAN, we assessed myelin ultrastructure via EM analysis (Fig. 3H). Concordant with the bright field images (Fig. 3E), we found substantially more myelinated axons in the cauda equina of cyclo-DPAKKR-treated groups compared with vehicle controls at both time points (Fig. 3H), further suggesting that cyclo-DPAKKR limits the extent of demyelination. It is well established that in patients with demyelinating peripheral neuropathy and animals with EAN, injured peripheral nerves commonly display patterns of macrophage-mediated demyelination such as phagocytosis of compact myelin lamellae following the displacement of the normal-appearing Schwann cell outer mesaxon from the compact myelin membrane (Carenini et al., 2001; Pollard and Armati, 2011). To determine if cyclo-DPAKKR reduced the extent of inflammatory demyelination, we
assessed EM images at a higher-magnification. We found that cyclo-oPAKKR treatment markedly limited the extent of macrophage-mediated demyelination in EAN compared with vehicle-treated animals (Fig. 3H). In the cauda equina of vehicle-treated rats, we readily observed compact myelin being stripped from an axon by a macrophage filled with myelin debris (Fig. 3H, panels a,a'), macrophage shown in panel a') and the normal appearing myelin sheath penetrated with macrophages (Fig. 3H, panels b,b'). However, these patterns of macrophage-mediated demyelination were rarely observed in the cauda equina of cyclo-oPAKKR-treated animals (Fig. 3H), suggesting a limited extent of inflammatory demyelination. The activation, proliferation and recruitment of phagocytic macrophages are a key innate cellular response that contributes to inflammatory demyelination in EAN (Xia et al., 2010). Having shown limited macrophage-mediated demyelination following cyclo-oPAKKR treatment in EAN (Fig. 3H), we next investigated macrophage infiltration in the injured peripheral nerves of these animals and found that cyclo-oPAKKR treatment significantly reduced the number of infiltrating IBa1+ macrophages in cauda equina sections at disease peak (day 17) compared with vehicle controls (*p < 0.001). Together, our data demonstrate that cyclo-oPAKKR exerts a protective effect on myelinated peripheral nerves subjected to EAN, in particular reducing the extent of demyelination.

Figure 2. Cyclo-oPAKKR ameliorates EAN in a dose-dependent manner. Time course of disease severity in rats subjected to EAN following daily administration of either vehicle control or Cyclo-oPAKKR from day 1 (data: mean ± SEM, n = 6–7/group, Mann–Whitney U test). A, Cyclo-oPAKKR reduced disease severity in rat EAN in a dose-dependent manner (3 mg/kg group: *p < 0.01, 10 mg/kg group: **p < 0.001). B, EAN rats treated with cyclo-oPAKKR beyond the disease peak (day 17) exhibited a significantly faster recovery compared with vehicle controls (p < 0.001).
Cyclo-DPAKKR reduces the extent of axonal damage in EAN

Increasing evidence suggests that myelin loss ultimately leads to the degeneration of exposed axons, which correlates with the progression of disability in human autoimmune-mediated peripheral demyelinating neuropathies and rodent EAN (Bechtold et al., 2005; Pollard and Armati, 2011; Kieseier et al., 2012). Having shown that cyclo-DPAKKR limits the extent of demyelination in EAN, we next sought to determine if it also limits axonal degeneration. To do this, we first assessed the accumulation of axonal spheroids containing APP, a robust indicator of axonal loss (Kieseier et al., 2012). We found that APP+ axonal spheroids (axonal spheroids of ~3–5 μm in diameter) were clearly visible in vehicle-treated animals (Fig. 4A, approximately ~5 per longitudinal section). Animals treated with cyclo-DPAKKR displayed a significant reduction in the accumulation of APP+ axonal spheroids compared with vehicle-treated control animals at both time points (Fig. 4A, quantitated in B, n = 3–4/group/time point, p < 0.05), suggesting that cyclo-DPAKKR exerts a neuroprotective effect on acute nerve damage in EAN.

It has been shown that disruptions of the nodal and paranodal architecture represent the site of axonal pathology in rodent EAN (Pollard and Armati, 2011) and in patients with chronic inflammatory demyelinating polyneuropathy (CIDP; Cifuentes-Diaz et al., 2011; Doppler et al., 2016). Thus, we investigated the expression of proteins normally clustered at the node of Ranvier and paranodes required for fast axonal conduction (Vabnick and Shragar, 1998). Longitudinal sections of the cauda equina were immunolabeled for voltage-gated sodium channels (pan-Nav) and Caspr, proteins normally expressed at the node of Ranvier and paranodes (Fig. 4A, C). In the chicken-treated group, we found significantly fewer pan-Nav-expressing nodes (Fig. 4D, p < 0.05) and Caspr-expressing paranodes (Fig. 4E, p < 0.05) compared with healthy (no EAN) control animals. However, these changes of nodal architecture in EAN are rescued by the treatment of cyclo-DPAKKR. We found cyclo-DPAKKR administration resulted in significantly more pan-Nav-expressing nodes (Fig. 4D, p < 0.05) and Caspr-expressing paranodes (Fig. 4E, p < 0.05) compared with vehicle-treated animals at both time points, suggesting a protective effect on nodal structure. We also observed that asymmetrical nodes and heminodes (Fig. 4C, arrows), an indicator of structural damage to nodes and paranodal demyelination in CIDP nerves (Cifuentes-Diaz et al., 2011), were visible in animals subjected to EAN but not in healthy control animals (data not shown). Quantification of the density of heminodes revealed significantly fewer heminodes in the nerves of cyclo-DPAKKR-treated animals compared with vehicle controls (Fig. 4F, p < 0.05), further suggesting that cyclo-DPAKKR protects the architecture of nodes and paranodes in EAN. Together, our data demonstrate that cyclo-DPAKKR reduces the extent of demyelination and protects against axonal damage in EAN.

Cyclo-DPAKKR exerts p75NTR-dependent therapeutic effects in EAN

The tripeptide ‘KKR’ motif is the region of BDNF that binds to p75NTR (Ryden et al., 1995). The head to tail DPro-Ala cyclisation of cyclo-DPAKKR presents the ‘KKR’ motif in the same structural conformation as BDNF (Fletcher et al., 2008). To determine if the beneficial effects of cyclo-DPAKKR exert on EAN is p75NTR-dependent, we synthesized a control cyclised peptide (cyclo-AopPKKR) containing the same ‘KKR’ p75NTR binding motif of cyclo-DPAKKR, but in a different conformation as it is contained by a different linker (Ala-LPro; Fig. 5A). We have previously shown that this altered conformational state can abolish the trophic effect that cyclo-DPAKKR exerts on peripheral neurons in vitro (Fletcher et al., 2008).

In this study, both cyclo-DPAKKR and the cyclised control peptide cyclo-AopPKKR were administered to mice subjected to EAN via daily intraperitoneal administration from day 1 for 23 d, and disease progression assessed by daily clinical scoring and DigiGait functional analysis (Fig. 5B,C). Concordant with the rat EAN data (Fig. 2), administration of cyclo-DPAKKR in murine EAN significantly ameliorated disease severity and delayed the onset of...
Figure 4. Cyclo-dPAKKR protected against axonal degeneration in EAN. Analyses of cauda equina isolated from rats subjected to EAN at day 17 or day 24 after daily treatment with Cyclo-dPAKKR (10 mg/kg) or vehicle control, or age-matched healthy control rats (no-EAN). A, B, Representative immunohistochemical images of APP (A) and quantitation of APP+ axonal spheroids (B) in longitudinal sections of cauda equina isolated from rats subjected to EAN. Administration of Cyclo-dPAKKR resulted in significantly fewer APP+...
continued

disease (~2 d) compared with the vehicle-treated control mice (Fig. 5B, n = 6 mice/group, ***p < 0.0001). In contrast, the structural control peptide cyclo-AoPKKR exerted no significant effect compared with vehicle-treated controls (Fig. 5B, n = 6 mice/group, p = 0.477). The finding that cyclo-oPAKKR, but not cyclo-AoPKKR, ameliorates EAN disease severity is also supported by the functional running task assessed by DigiGait analysis. All EAN mice were subjected to a regular running task assessment every 3 d and the running time before failure were analyzed (Fig. 5C). We found both the vehicle and control peptide-treated mice began to display a significant drop in their running time from day 9 to 11, whereas the running time of cyclo-oPAKKR-treated mice did not show a significant drop until approximately day 20 (Fig. 5C, *p < 0.05, n = 6 mice/group), suggesting an ameliorated motor deficit. Moreover, cyclo-oPAKKR-treated mice displayed a significantly prolonged running time compared with the vehicle control group from day 9 onwards (Fig. 5C, *p < 0.05, n = 6 mice/group), further suggesting better motor performance. In contrast, the control peptide exerted no significant influence on running capacity compared with the vehicle control (Fig. 5C).

Collectively, these results suggest that the conformational constraint component within cyclo-oPAKKR itself determines its therapeutic effect by facilitating its interaction with p75NTR. Our findings that the control peptide cyclo-AoPKKR failed to influence the disease course and motor capacity of mice subjected to EAN indicate that the therapeutic effect of cyclo-oPAKKR is not due to an immune-mediated effect possibly caused by treatment with a peptide.

We further went to determine if cyclo-oPAKKR exerted its effects in a p75NTR-dependent manner using p75NTR HET mice. As p75NTR KO (−/−) mice display a developmental loss of >50% sensory neurons in the PNS (Lee et al., 1992; Murray et al., 1999) potentially confounding interpretation in this study, p75NTR HET mice were used. P75NTR HET and WT littermate control mice were induced with EAN, and either untreated, or treated with cyclo-oPAKKR or cyclo-AoPKKR (the control peptide) daily from day 1 for 23 d. Daily clinical scoring revealed no significant difference between disease progression in the untreated p75NTR HET and control WT mice (data not shown), suggesting that p75NTR haploinsufficiency does not influence EAN severity and progression. We found that the clinical scores of p75NTR HET mice treated with cyclo-oPAKKR were significantly higher compared with cyclo-oPAKKR-treated WT mice (Fig. 6A, n = 6 mice/genotype/group, ****p < 0.0001), suggesting that p75NTR haploinsufficiency attenuates cyclo-oPAKKR’s therapeutic effect. In contrast, the control peptide (cyclo-AoPKKR) exerted no significant effect on disease course between genotypes (Fig. 6C, n = 6 mice/genotype/group). These data further support the perspective that the conformational constraint component within cyclo-oPAKKR itself is critical for this effect, which is consistent with the data shown in Figure 5B.

Moreover, there was no significant difference in disease severity between cyclo-oPAKKR and control peptide treatment in p75NTR HET (Fig. 6E, n = 6 mice/genotype/group). These clinical scores data are supported by the functional motor performance assessed by Digi-gait analysis (Fig. 6B,D,F). We found that WT mice treated with cyclo-oPAKKR performed significantly better in a running task compared with cyclo-oPAKKR-treated HET mice, as evidenced by a significantly prolonged running time (Fig. 6B, n = 6 mice/genotype/group, *p < 0.05). In contrast, the control peptide (cyclo-AoPKKR) exerted no significant influence on running capacity between genotypes (Fig. 6D, n = 6 mice/genotype/group). In addition, there is no significant difference in running times between cyclo-oPAKKR or control peptide-treated p75NTR HET mice (Fig. 6F, n = 6 mice/genotype/group). Together, our results demonstrate that p75NTR haploinsufficiency attenuates cyclo-oPAKKR’s beneficial effect on ameliorating clinical and functional deficits induced by EAN, suggesting that p75NTR expression is necessary for the therapeutic influence that cyclo-oPAKKR exerts on EAN.

**Cyclo-oPAKKR exerts a p75NTR-dependent effect on neuropathology in EAN**

To identify neuropathological evidence of a p75NTR-dependent therapeutic effect of cyclo-oPAKKR in EAN, we next assessed the extent of demyelination and axonal degeneration via histology. It has recently been demonstrated that myelin has unique physical properties making it the only structure within neural tissues capable of reflecting light (Schain et al., 2014). To take advantage of the high refractive index of lipid-rich compact myelin, the SCRe imaging method has been recently developed to assess myelinated axons in vivo in both healthy and pathologic conditions (Schain et al., 2014). Here, we examined the extent of myelin damage on longitudinal sections of sciatic nerve from mice subjected to EAN using SCRe imaging (Fig. 7A,B). We found that WT mice treated with cyclo-oPAKKR demonstrate a significantly higher percentage of reflected signal compared with mice treated with the control peptide (Fig. 7A, quantitated in B, *p < 0.05), indicating a greater percentage of compact myelin per area assessed. Concordant with the clinical and functional assessments (Fig. 6), cyclo-oPAKKR exerted no significant influence on SCRe signal in p75NTR
Figure 5. Conformational constraint in Cyclo-dPAKKR determines its therapeutic effect on EAN. A, The sequence structure of the cyclic pentapeptide Cyclo-dPAKKR and its control peptide (cyclo-ADPKKR). Cyclo-dPAKKR is a circular peptide containing a tripeptide motif (KKR) from BDNF shown to bind to p75NTR. Cyclo-ADPKKR (control peptide) is also a cyclic pentapeptide containing the same p75NTR-binding motif as Cyclo-dPAKKR, but with altered position of Ala and DPro. The five amino acid residues for both peptides are indicated. B, Time courses of EAN disease severity following daily intraperitoneal delivery of either vehicle, cyclo-dPAKKR (10 mg/kg/d) or control peptide (cyclo-ADPKKR, 10 mg/kg/d) in mice after disease induction from day 1. Clinical scores: 0,
HET mice compared with the control peptide (Fig. 7A,B), indicating that cyclo-ôPAKKR requires the expression of p75NTR to confer beneficial influence on myelin in EAN. Widening of the node of Ranvier, an indicator of demyelination and axonal damage, is one of the pathologic features commonly observed in peripheral demyelinating neuropathy (Griffin et al., 1996). Next we examined if cyclo-ôPAKKR treatment can influence nodal widening in EAN mice via measuring the distance between the paired Caspr+ paranodes in longitudinal sciatic nerve sections of mice treated with cyclo-ôPAKKR or control peptide (Fig. 7C, quantitated in D). Caspr+ heminodes were excluded from this analysis. We found that the node length is significantly shorter in WT mice treated with cyclo-ôPAKKR compared with those treated with control peptide (Fig. 7D, *p < 0.05), suggesting that cyclo-ôPAKKR protects against nodal widening. Moreover, cyclo-ôPAKKR failed to influence nodal length widening in p75NTR HET mice (Fig. 7C,D). There was no significant difference in the nodal length between WT and p75NTR HET mice treated with the control peptide (Fig. 7C,D). Collectively, our data suggest that cyclo-ôPAKKR requires the normal expression of p75NTR to exert its beneficial influence on nodal structures and axonal damage in EAN.

We further investigated whether cyclo-ôPAKKR exerts p75NTR-dependent effects on axonal degeneration via assessing the accumulation of APP in mice subjected to EAN (Fig. 7E,F). APP+ axonal spheroids were readily visible along injured peripheral nerves in the rat model of EAN (Fig. 4A); however, only APP+ axonal segments, but not axonal spheroids, were observed in the murine model of EAN (Fig. 7E), suggesting the extent of overall axonal degeneration is less severe in the murine EAN model compared with the rat model. As such we decided to analyze the percentage of APP+ immunostaining that was colocalized with the neuronal marker βIII-tubulin (a mask was created using the βIII-tubulin signal and the percentage area of positive APP+ signal was computed; Fig. 7E, quantitated in F). We found that in WT mice, cyclo-ôPAKKR treatment significantly reduced the percentage of APP+βIII-tubulin+ colocalization compared with the control peptide group (Fig. 7E, quantitated in F, *n = 3 mice/genotype/group, ***p < 0.001), supporting our data observed in rat EAN (Fig. 4A). Concordant with clinical, functional and myelin assessments (Figs. 6 and 7A-D), the protective effect that cyclo-ôPAKKR exerts against axonal degeneration is abolished in p75NTR HET mice, in which cyclo-ôPAKKR exerts no significant influence on the percentage of APP+ axonal area compared with the control peptide-treated group (Fig. 7E,F). Moreover, we found that control peptide treatment exerted no significant effect on the percentage of APP+ axonal area between genotypes (Fig. 7E,F). Together, our data provide strong neuropathological evidence that p75NTR expression is required for the protective effects that cyclo-ôPAKKR exerts against myelin and axonal pathology in EAN, indicating that it ameliorates EAN-induced neuropathology in a p75NTR-dependent manner.

**Discussion**

In this study, we show that a conformationally constrained BDNF-based p75NTR peptide ameliorates functional, axonal and myelin pathologies induced by EAN disease in both rats and mice. Importantly, these beneficial effects are abolished when the genetic dose of the p75NTR is halved. Together, our data suggest that targeting p75NTR is a novel therapeutic strategy that ameliorates demyelination and axonal degeneration induced by peripheral demyelinating diseases.

**Cyclo-ôPAKKR limits the extent of functional deficits and neuropathology in EAN**

The altered expression of the neurotrophins and p75NTR in experimental models of peripheral nerve injury and in a range of human peripheral neuropathies (Yamamoto et al., 1998) has resulted in speculation that the neurotrophins could be involved in the pathogenesis and repair of these diseases (Pittenger and Vinik, 2003; Anand, 2004; Zhou and Notterpek, 2016). Two recent studies have investigated the potential of using BDNF as a therapeutic strategy to treat peripheral demyelinating neuropathy. Treatment with recombinant BDNF in rat EAN failed to improve neurologic and motor deficits (Felts et al., 2002). Further, transplantation of BDNF-treated Schwann cells also failed to ameliorate rat EAN (Hou et al., 2013). Consistent with these findings, we found that administration of recombinant BDNF failed to promote the myelination of developing peripheral nerves in vivo (Xiao et al., 2013), although it is able to enhance Schwann cell myelination in vitro (Xiao et al., 2009b). These studies together demonstrate that BDNF itself is not an optimal therapeutic candidate for treating demyelinating diseases. While the precise reason why BDNF exerts no beneficial effect on myelination during development and rodents subjected to EAN in vivo remains unclear, it is important to be cognizant of the poor drug-like properties of BDNF and the complexity of BDNF signaling (Chao, 2003), in particular in the context of myelination (Xiao et al., 2009b). In this case, we have identified that targeting of p75NTR, a positive regulator of both peripheral neuron survival and myelination (Lee et al., 1992; Cosgaya et al., 2002; Xiao et al., 2009b), could be a new approach that can protect the PNS after injury.
Figure 6. Cyclo-oPAKKR ameliorates EAN in a p75NTR-dependent manner. **A, C, E**, Time courses of EAN disease severity following daily intraperitoneal delivery of either cyclo-oPAKKR (10 mg/kg/d) or control peptide (cyclo-AoPKKR, 10 mg/kg/d) in p75NTR HET or WT littermate control mice after disease induction from day 1 (n = 5–6 mice/genotype/group). **B, D, F**, Running times before failure in a DidgiGait treadmill running task (speed, 15 cm s⁻¹). **A, B**, Cyclo-oPAKKR significantly reduced mean clinical scores (A) and improved running capacity (B) in WT mice compared with HET mice (data: mean ± SEM, two-way ANOVA with repeated measures, ****p < 0.0001 and *p < 0.05). **C, D**, No significant difference in clinical scores (C) and running times (D) between WT and HET mice treated with the control peptide (cyclo-AoPKKR). **E, F**, No significant difference in clinical scores (E) and running times (F) between for HET mice treated with cyclo-oPAKKR or control peptide.
Figure 7. Cyclo-oPAKKR reduces demyelination and axonal degeneration in a p75NTR-dependent manner. Histologic analyses of longitudinal sciatic nerve sections of EAN mice following daily treatment of either cyclo-oPAKKR (10 mg/kg) or control peptide (cyclo-AoPAKKR, 10 mg/kg) in p75NTR HET or WT littermate control mice from day 1. All tissues were collected at day 23 (disease peak). Data: mean ± SEM, 95% confidence interval, ANOVA with Tukey’s post hoc testing n = 3 mice/genotype/group, *p < 0.05, **p < 0.01, ***p < 0.001. A, B, Representative ScCoRe images (A) and quantification (B) of ScCoRe signal as a percentage of total area measured. WT mice treated with cyclo-oPAKKR display a greater percentage area of ScCoRe reflected signal than control peptide, indicating more myelinated axons. Cyclo-oPAKKR exerts no significant influence on HET mice compared with control peptide (scale bar, 200 μm). C, D, Representative images (C) of Caspr immunostaining and quantification (D) of node distance between adjacent Caspr+ paranodes. WT mice treated with cyclo-oPAKKR demonstrate significantly shorter mean node distance compared with mice treated with control peptide. Cyclo-oPAKKR exerts no significant influence on HET mice compared with control peptide (scale bar, 1 μm, minimum 70 nodes per mouse). E, F, Representative images (E) of APP and βIII-tubulin double immunostaining and quantification (F) of the percentage of APP+ axonal area colocalizing with βIII-tubulin. Cyclo-oPAKKR treatment significantly reduced the percentage of APP+ colocalization with βIII-tubulin compared with the control peptide in WT, but not in HET mice (scale bar, 5 μm; scale in inset, 20 μm).

We have previously identified that cyclo-oPAKKR promotes the survival and myelination of peripheral neurons (Fletcher et al., 2008; Fletcher and Hughes, 2009; Xiao et al., 2013). In this study, we have demonstrated that cyclo-oPAKKR administration significantly ameliorated EAN disease severity and accelerated recovery compared with controls. Cyclo-oPAKKR-treated animals displayed significantly better motor performance compared with both vehicle and control peptide-treated groups. Moreover, these functional benefits of cyclo-oPAKKR are strongly supported by the limited extent of neuropathology, as evident by reduced demyelination and axonal damage as well as immune cell infiltration in injured nerves compared with control groups. Importantly, analysis of the node of Ranvier revealed that the loss of Nav-expressing domains, disruption of paranodal structures and widening of the nodal length, as are also observed in human peripheral demyelinating neuropathy (Griffin et al., 1996; Pollard and Armati, 2011), were attenuated in cyclo-oPAKKR-treated animals. This finding is particularly interesting as it suggests that cyclo-oPAKKR treatment exerts protective effects on the axo-glial junction and reduces the extent of paranodal demyelination in EAN. There is an emerging consensus that the progression of disability in human peripheral demyelinating neuropathy (Griffin et al., 1996; Pollard and Armati, 2011; Kieseler et al., 2012). Together, our data indicate that cyclo-oPAKKR treatment either reduces the extent of demyelination, or promotes more complete remyelination, with the net effect of reducing axonal damage, providing strong anatomic evidence that supports the improved functional outcomes in EAN.

Cyclo-oPAKKR’s effects are p75NTR dependent

Both BDNF and cyclo-oPAKKR have previously been shown to promote peripheral nerve myelination via p75NTR (Xiao et al., 2009b, 2013). In this study, our data consistently demonstrate that p75NTR expression is required for the beneficial influence that cyclo-oPAKKR exerts on EAN disease severity, motor function, myelin and axonal pathology. It is interesting that cyclo-oPAKKR failed to ameliorate EAN induced disease in p75NTR HET mice that still express p75NTR, but at a reduced level, suggesting that the beneficial effect of cyclo-oPAKKR may require a threshold level of p75NTR expression, which ultimately leads to optimal downstream p75NTR signaling. This speculation can also partially explain our finding that cyclo-oPAKKR exerts a dose-dependent effect on EAN. Nevertheless, our data strongly suggest that cyclo-oPAKKR exerts a therapeutic effect on EAN which is dependent on p75NTR expression. This is further supported by the finding that the cyclised control peptide (cyclo-AoPKKR), that contains the same ‘KKR’ p75NTR binding motif, does not exert protective effects on EAN. This result indicates that the beneficial effects that cyclo-oPAKKR exerts on EAN are crucially dependent on the proper conformation of the ‘KKR’ p75NTR binding motif. The lack of effect of cyclo-AoPKKR compared with cyclo-oPAKKR reflects our previous observations when examining neuronal survival in vitro (Fletcher et al., 2008). We have previously shown that cyclo-oPAKKR adopts a highly constrained conformation in solution (Fletcher et al., 2008). It is therefore not surprising that even a seemingly modest change in the linker could lead to a dramatic change in conformational preference, sufficient to alter ligand-receptor interactions and subsequent downstream signaling. Ultimately, a greater understanding of the molecular interaction, specificity, binding affinity and stoichiometry between cyclo-oPAKKR and p75NTR is required to definitively identify the molecular basis of the differential effects of cyclo-oPAKKR and cyclo-AoPKKR on EAN.

At a cellular level, it remains interesting to determine the cell type(s) that cyclo-oPAKKR targets to ameliorate EAN. It is well established that p75NTR is expressed in neurons and Schwann cells, and it promotes the viability of subsets of peripheral neurons (Lee et al., 1992; Murray et al., 1999) and influences Schwann cell myelination (Cosgaya et al., 2002; Chan et al., 2006) during development. We and others have shown that p75NTR KO mice display a loss of >50% sensory neurons compared with WT mice (Lee et al., 1992; Murray et al., 1999). It has, however, been uncertain as to whether this effect is mediated via loss of p75NTR signaling in isolation, or whether it is due to the loss of signaling through “high-affinity” neurotrophin receptor complexes (i.e. p75NTR in combination with the Trk receptors). Interestingly, we have previously demonstrated that cyclo-oPAKKR promotes the survival of purified embryonic chick sensory neurons in culture (Fletcher et al., 2008), strongly suggesting that selective p75NTR...
induced signaling is neurotrophic. In this study, we found that cyclo-PAKKR administration significantly protected against EAN-induced axonal damage, suggesting a neuroprotective effect. These findings collectively suggest that cyclo-PAKKR administration in the context of demyelinating neuropathies may not only limit demyelination but also potentially directly ameliorate secondary axonal degeneration and neuronal loss. Further, we have previously identified that cyclo-PAKKR selectively targets neuronally expressed p75NTR to promote peripheral nerve myelination (Xiao et al., 2013). Thus, it is plausible that cyclo-PAKKR could directly target neurons to promote both their survival and remyelination, thus effectively ameliorating EAN-induced neuropathology, which ultimately determines disease progression and severity.

Interestingly, macrophages and T cells also express p75NTR (Flügel et al., 2001; Pérez-Piñera et al., 2006). In addition, our data also show that cyclo-PAKKR reduced immune cell infiltration into affected peripheral nerves, suggesting cyclo-PAKKR may act by more than one mechanism to ameliorate disease severity in EAN. However, based on clinical scoring, cyclo-PAKKR-treated EAN animals still become sick, indicating that cyclo-PAKKR itself does not block antigen presentation or the induction of T-cells. We have shown that neither injection of p75NTR antisense oligonucleotides nor the genetic knockout of p75NTR impedes the induction of experimental autoimmune encephalomyelitis (Soiliu-Hanninen et al., 1999), a T-cell-mediated autoimmune disease in the CNS that has similar pathogenesis to EAN in the PNS. Collectively, this suggests that macrophage expression of p75NTR may not play a significant role in EAN induction, but it nevertheless remains unclear whether the observed decrease in infiltrating macrophages is a direct effect on the macrophages themselves, or is an indirect effect secondary to myelin repair.

While the utility of p75NTR heterozygous mice, in which there is a global p75NTR haploinsufficiency, enabled identification of the requirement of p75NTR for cyclo-PAKKR to exert its therapeutic benefit, it does not enable direct insight into the specific pathologic processes that cyclo-PAKKR influences. Whether this is reduced axonal damage, enhanced myelin repair or immunomodulation remains unclear. This technical limitation precludes identification of a clear-cut cellular mechanism underlying the beneficial effects that cyclo-PAKKR exerts on EAN. Thus, future studies are required to determine the precise mechanisms of cyclo-PAKKR action through adopting inducible genetic approaches in which p75NTR is selectively deleted from peripheral neurons, Schwann cells or immune cells in the adult PNS, without interfering with the normal development of these cells. Future experiments are also required to determine the therapeutic efficacy of cyclo-PAKKR on EAN under different treatment paradigms, such as commencing treatment after disease symptoms appear.

In summary, we have identified that cyclo-PAKKR, a structural mimetic of the region of BDNF that binds to p75NTR, ameliorates EAN disease severity and functional deficits accompanied by strong neuroprotection against myelin and axonal damage, effects dependent on p75NTR expression. Interestingly, cyclo-PAKKR itself displays drug-like properties, in that it is of low molecular weight, metabolically stable and readily crosses cell membranes (Fletcher et al., 2008; Fletcher and Hughes, 2009). Demyelination followed by axonal damage is a common and integral component of demyelinating diseases, and our work identifying cyclo-PAKKR exerts p75NTR-dependent neuroprotective effects on EAN provides new insight into the future development of neuroprotective therapeutics for peripheral demyelinating diseases.

References


May/June 2017, 4(3) e0142-17.2017 eNeuro.org


A Brain-Derived Neurotrophic Factor-Based p75(NTR) Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination

Date:
2017-05-01

Citation:

Persistent Link:
http://hdl.handle.net/11343/212468

File Description:
Published version

License:
CC BY